BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32617865)

  • 21. Antifungal activity of
    Almeida-Apolonio AA; Dantas FGDS; Rodrigues AB; Cardoso CAL; Negri M; Oliveira KMP; Chang MR
    Nat Prod Res; 2019 Aug; 33(16):2363-2367. PubMed ID: 29463129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro and in vivo.
    Zhai B; Lin X
    Int J Antimicrob Agents; 2013 Mar; 41(3):250-4. PubMed ID: 23313397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans.
    Ganendren R; Widmer F; Singhal V; Wilson C; Sorrell T; Wright L
    Antimicrob Agents Chemother; 2004 May; 48(5):1561-9. PubMed ID: 15105106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Theranostic of Cryptococcal Encephalitis by a Novel Polypyridyl Ruthenium Complex.
    Wang Q; Fu C; Zhao Z; Fu A
    Mol Pharm; 2020 Jan; 17(1):145-154. PubMed ID: 31800255
    [No Abstract]   [Full Text] [Related]  

  • 28. Antifungal Activity, Antibiofilm and Association Studies with O-Alkylamidoximes against Cryptococcus spp.
    de Castro Teixeira AP; Fernandes Queiroga Moraes G; de Oliveira RJ; Silva Santos C; Alves Caiana RR; Rufino de Freitas JC; Vasconcelos U; de Oliveira Pereira F; Oliveira Lima I
    Chem Biodivers; 2023 Mar; 20(3):e202200539. PubMed ID: 36730650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A titanic drug resistance threat in Cryptococcus neoformans.
    Zafar H; Altamirano S; Ballou ER; Nielsen K
    Curr Opin Microbiol; 2019 Dec; 52():158-164. PubMed ID: 31765991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Antimicrobial Peptide MK58911-NH
    Singulani JL; Oliveira LT; Ramos MD; Fregonezi NF; Gomes PC; Galeane MC; Palma MS; Fusco Almeida AM; Mendes Giannini MJS
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0090421. PubMed ID: 34516241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G
    J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M; Liao Y; Chen M; Pan W; Weng L
    Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.
    Zhai B; Wu C; Wang L; Sachs MS; Lin X
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3758-66. PubMed ID: 22508310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
    Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective inhibition of Cbf-14 against Cryptococcus neoformans infection in mice and its related anti-inflammatory activity.
    Yu C; Wei S; Han X; Liu H; Wang M; Jiang M; Guo M; Dou J; Zhou C; Ma L
    Fungal Genet Biol; 2018 Jan; 110():38-47. PubMed ID: 29221882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
    Bejar V; Tello M; García R; Guevara JM; Gonzales S; Vergaray G; Valencia E; Abanto E; Ortega-Loayza AG; Hagen F; Gutierrez EL
    Rev Iberoam Micol; 2015; 32(2):88-92. PubMed ID: 25556051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
    Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
    Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis.
    Kano R; Okubo M; Yanai T; Hasegawa A; Kamata H
    Mycopathologia; 2015 Dec; 180(5-6):427-33. PubMed ID: 26162642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.